Gender-affirming care, mental health, and economic stability in the time of COVID-19: a global cross-sectional study of transgender and non-binary people.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
04 Nov 2020
04 Nov 2020
Historique:
entrez:
11
11
2020
pubmed:
12
11
2020
medline:
12
11
2020
Statut:
epublish
Résumé
Transgender and non-binary people are disproportionately burdened by barriers to quality healthcare, mental health challenges, and economic hardship. This study examined the impact of the novel coronavirus disease (COVID-19) pandemic and subsequent control measures on gender-affirming care, mental health, and economic stability among transgender and non-binary people globally. We collected global cross-sectional data from 964 transgender and non-binary adult users of the Hornet and Her apps from April to August 2020 to characterize changes in gender-affirming care, mental health, and economic stability as a result of the COVID-19 pandemic. We conducted Poisson regression models to assess if access to gender-affirming care and ability to live according to one's gender were related to depressive symptoms, anxiety, and changes in suicidal ideation. Individuals resided in 76 countries, including Turkey (27.4%,n=264/964) and Thailand (20.6%,n=205). A majority were non-binary (66.8%,n=644) or transfeminine (29.4%,n=283). Due to the COVID-19 pandemic, 55.0% (n=320/582) reported reduced access to gender- affirming resources, and 38.0% (n=327/860) reported reduced time lived according to their gender. About half screened positive for depression (50.4%,442/877) and anxiety (45.8%,n=392/856). One in six (17.0%,n=112/659) expected losses of health insurance, and 77.0% (n=724/940) expected income reductions. The prevalence of depressive symptoms, anxiety, and increased suicidal ideation were 1.63 (95% CI: 1.36-1.97), 1.61 (95% CI: 1.31-1.97), and 1.74 (95% CI: 1.07-2.82) times higher for individuals whose access to gender- affirming resources was reduced versus not. The COVID-19 pandemic has reduced access to gender-affirming resources and the ability of transgender and non-binary people to live according to their gender worldwide. These reductions may drive the increased depressive symptoms, anxiety, and suicidal ideation reported in this sample. To improve transgender and non-binary health globally, increased access to gender-affirming resources should be achieved through policies (e.g., digital prescriptions), flexible interventions (e.g., telehealth), and support for existing transgender health initiatives.
Sections du résumé
BACKGROUND
BACKGROUND
Transgender and non-binary people are disproportionately burdened by barriers to quality healthcare, mental health challenges, and economic hardship. This study examined the impact of the novel coronavirus disease (COVID-19) pandemic and subsequent control measures on gender-affirming care, mental health, and economic stability among transgender and non-binary people globally.
METHODS
METHODS
We collected global cross-sectional data from 964 transgender and non-binary adult users of the Hornet and Her apps from April to August 2020 to characterize changes in gender-affirming care, mental health, and economic stability as a result of the COVID-19 pandemic. We conducted Poisson regression models to assess if access to gender-affirming care and ability to live according to one's gender were related to depressive symptoms, anxiety, and changes in suicidal ideation.
RESULTS
RESULTS
Individuals resided in 76 countries, including Turkey (27.4%,n=264/964) and Thailand (20.6%,n=205). A majority were non-binary (66.8%,n=644) or transfeminine (29.4%,n=283). Due to the COVID-19 pandemic, 55.0% (n=320/582) reported reduced access to gender- affirming resources, and 38.0% (n=327/860) reported reduced time lived according to their gender. About half screened positive for depression (50.4%,442/877) and anxiety (45.8%,n=392/856). One in six (17.0%,n=112/659) expected losses of health insurance, and 77.0% (n=724/940) expected income reductions. The prevalence of depressive symptoms, anxiety, and increased suicidal ideation were 1.63 (95% CI: 1.36-1.97), 1.61 (95% CI: 1.31-1.97), and 1.74 (95% CI: 1.07-2.82) times higher for individuals whose access to gender- affirming resources was reduced versus not.
DISCUSSION
CONCLUSIONS
The COVID-19 pandemic has reduced access to gender-affirming resources and the ability of transgender and non-binary people to live according to their gender worldwide. These reductions may drive the increased depressive symptoms, anxiety, and suicidal ideation reported in this sample. To improve transgender and non-binary health globally, increased access to gender-affirming resources should be achieved through policies (e.g., digital prescriptions), flexible interventions (e.g., telehealth), and support for existing transgender health initiatives.
Identifiants
pubmed: 33173876
doi: 10.1101/2020.11.02.20224709
pmc: PMC7654856
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIMH NIH HHS
ID : F31 MH121128
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH114715
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI102623
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Ann Epidemiol. 2020 Jul;47:37-44
pubmed: 32419766
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
Clin Psychol Rev. 2018 Dec;66:24-38
pubmed: 29627104
Lancet. 2016 Jul 23;388(10042):412-436
pubmed: 27323919
Lancet Diabetes Endocrinol. 2020 Jul;8(7):564-565
pubmed: 32445629
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049-1057
pubmed: 32790653
J Adolesc Health. 2020 Nov;67(5):645-648
pubmed: 32933837
J Sex Res. 2016;53(1):85-97
pubmed: 25621903
Am J Psychiatry. 2020 Aug 1;177(8):727-734
pubmed: 31581798
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
Transgend Health. 2018 Dec 14;3(1):170-178
pubmed: 30564633
Qual Health Res. 2017 Dec;27(14):2138-2149
pubmed: 28836483
PLoS One. 2020 Feb 21;15(2):e0228765
pubmed: 32084144
AIDS Behav. 2020 Jul 11;:
pubmed: 32654021
Global Health. 2020 Jul 6;16(1):57
pubmed: 32631403
J Adolesc Health. 2020 Sep;67(3):450-452
pubmed: 32591304
Nutrients. 2020 Jul 15;12(7):
pubmed: 32679788
AIDS Care. 2007 Jan;19(1):28-33
pubmed: 17129855
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
Soc Sci Med. 2015 Dec;147:222-31
pubmed: 26599625
Clin Chem. 2019 Jan;65(1):119-134
pubmed: 30602477
J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):e90-e92
pubmed: 32947443
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1133-1138
pubmed: 32817604
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32819917
Lancet Psychiatry. 2020 Sep;7(9):813-824
pubmed: 32682460
AIDS Behav. 2020 Sep;24(9):2477-2479
pubmed: 32338329
Arch Sex Behav. 2013 Apr;42(3):327-30
pubmed: 23440563
Curr Psychiatry Rep. 2018 Oct 11;20(12):110
pubmed: 30306351
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Urol Clin North Am. 2019 Nov;46(4):475-486
pubmed: 31582022
Wellcome Open Res. 2020 May 6;5:88
pubmed: 32613083
AIDS Behav. 2020 Jul;24(7):2009-2012
pubmed: 32415617
Arch Sex Behav. 2020 Feb;49(2):645-659
pubmed: 31485801
Health Serv Res. 2019 Dec;54 Suppl 2:1454-1466
pubmed: 31659745
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):e67-e69
pubmed: 33136755
Sex Roles. 2013 Jun 1;68(11-12):675-689
pubmed: 23729971
Cult Health Sex. 2017 Jan;19(1):64-75
pubmed: 27300085
Clin Endocrinol (Oxf). 2010 Feb;72(2):214-31
pubmed: 19473181
Arch Sex Behav. 2020 Jul;49(5):1395-1399
pubmed: 32519279
Health Soc Work. 2019 Aug 2;44(3):149-155
pubmed: 31359065
Neuropsychiatr Dis Treat. 2016 Aug 04;12:1953-66
pubmed: 27536118
Int J Transgend. 2019 Jul 25;20(2-3):119-125
pubmed: 32999599